Table 2 Given treatments and features of intensive care in the identified NORSE subgroups
From: Early clinical features of new-onset refractory status epilepticus (NORSE) in adults
All patients (n = 19) | FIRES (n = 6) | Viral encephalitis (n = 5) | Afebrile NORSE group (n = 8) | FIRES vs non-FIRES | |
|---|---|---|---|---|---|
Number of antiseizure medications | 4 (4-8) | 9 (8-9) | 3 (3-4) | 4 (4-5) | p = 0.001 |
Number of anesthetics | 2 (1-3) | 4 (2-4) | 1 (1-2) | 1 (1-2) | p = 0.002 |
Antimicrobial medication | 16 (84%) | 6 (100%) | 5 (100%) | 5 (62.5%) | NS |
Immunotherapy | 7 (37%) | 5 (83%) | 1 (20%) | 1 (12.5%) | 0.01 |
STESS | 4 (3-4) | 4 (4-4) | 3 (3-4) | 4 (4-5) | NS |
CBI-score | 4 (2-9) | 9 (7-9) | 2 (1-3) | 4 (2-4) | p < 0.001 |
Days in tertiary hospital | 29 (15-59) | 96 (78-152) | 17 (15-29) | 21 (10-33) | p = 0.017 |
Days in intensive care unit | 16 (10-48) | 69 (56-135) | 12 (10-17) | 11 (7-17) | p = 0.012 |
Days in anesthesia | 4 (2-28) | 54 (34-125) | 2 (2-3) | 3 (2-6) | p = 0.007 |